Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

I. Blancas¹ · M. Fontanillas² · V. Conde³ · J. Lao⁴ · E. Martínez⁵ · M. J. Sotelo⁶ · A. Jaen⁷ · J. L. Bayo⁸ · F. Carabantes⁹ · J. J. Illarramendi¹⁰ · M. M. Gordon¹¹ · J. Cruz¹² · A. García-Palomo¹³ · C. Mendiola¹⁴ · E. Pérez-Ruiz¹⁵ · J. S. Bofill¹⁶ · J. M. Baena-Cañada¹⁷ · N. M. Jáñez¹⁸ · G. Esquerdo¹⁹ · M. Ruiz-Borrego²⁰

Published online: 3 October 2018

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Correction to: Clin Transl Oncol (2018) 20:862–869
<https://doi.org/10.1007/s12094-017-1797-9>

An information under Table 2 was published incorrectly. The correct data should read as follows:

Visceral involvement

No 225 10.6 (8.9–11.6) 0.6604 212 121 (57.1) 0.7169
Yes 38 10.0 (7.1–13.9) 36 19 (52.8)

The corrected table is given in the following page:

The original article can be found online at <https://doi.org/10.1007/s12094-017-1797-9>.

✉ I. Blancas
iblanca@ugr.es

¹ Hospital Universitario Clínico San Cecilio, Complejo Hospitalario Universitario, C/Dr. Oloriz, 16, 18012 Granada, Spain

² Hospital Clinic de Barcelona, illarroel, 170, 08036 Barcelona, Spain

³ Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas, S/N, 18014 Granada, Spain

⁴ Hospital Universitario Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain

⁵ Hospital Provincial de Castellón, Av. del Dr. Clarà, 19, 12002 Castelló de la Plana, Spain

⁶ Hospital Universitario Clínico San Carlos, C/del Profesor Martín Lagos, s/n, 28040 Madrid, Spain

⁷ Hospital de Jaén, Avda. del Ejército Español, nº 10, 23007 Jaén, Spain

⁸ Hospital Juan Ramón Jiménez, Ronda Exterior Norte s/n, 21005 Huelva, Spain

⁹ Hospital Universitario Carlos Haya, Av. de Carlos Haya, s/n, 29010 Málaga, Spain

¹⁰ Complejo Universitario Hospital de Navarra, Calle Irunlarrea, 3, 31008 Pamplona, Spain

¹¹ Hospital de Jerez, Ronda de Circunvalación s/n, 11407 Cádiz, Spain

¹² Hospital Universitario de Canarias, Carretera de Ofra, s/n, 38320 Santa Cruz de Tenerife, Spain

¹³ Complejo Universitario Asistencial de León, C/Altos de Nava, s/n, León, Spain

¹⁴ Hospital Universitario, 12 de Octubre, Avenida de Córdoba, s/n, 28041 Madrid, Spain

¹⁵ Hospital Costa del Sol, Autovia A-7, Km 187, 29603 Marbella, Spain

¹⁶ Hospital Nuestra Señora De Valme, Av. de Bellavista, s/n, 41014 Seville, Spain

¹⁷ Hospital Universitario Puerta del Mar, Av. Ana de Viya, 21, 11009 Cádiz, Spain

¹⁸ Hospital Ramón y Cajal, Ctra. de Colmenar Viejo, km. 9,100, 28034 Madrid, Spain

¹⁹ Clínica Benidorm, Av. Alfonso Puchades, 03501 Benidorm, Spain

²⁰ Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, s/n, 41013 Seville, Spain

Table 2 Progression-free survival according to subgroups of patients

	PFS (months)			CBR (CR + PR + SD $\geq$ 24 months)		
	<i>N</i>	Median (95% CI)	<i>p</i> value	<i>N</i>	<i>n</i> (%)	<i>p</i> value
Histologic type						
Ductal	208	11.2 (9.9–13.0)	0.0002	196	115 (58.7)	0.0635
Lobular	37	7.8 (5.6–10.9)		34	14 (41.2%)	
Hormonal receptors						
ER+ PgR+	197	10.8 (9.1–12.1)	0.6725	189	114 (60.3)	0.0088
ER+ PgR–	61	8.9 (6.8–11.2)		55	22 (40.0%)	
p53						
Positive (> 15%)	19	13.6 (5.8–NE)	0.4591	18	10 (55.6)	1.0000
Negative	95	9.2 (7.6–10.9)		90	51 (56.7%)	
Ki67						
Positive (> 20%)	70	9.6 (6.5–13.1)	0.7224	66	34 (51.5)	0.2917
Negative	72	10.0 (7.8–12.9)		66	41 (62.1)	
HER2 status						
Positive	26	10.2 (7.7–13.3)	0.6809	24	12 (50.0)	0.5209
Negative	206	10.3 (8.0–11.3)		196	112 (57.1)	
ECOG score						
0–1	221	10.9 (9.6–12.6)	0.0061	210	123 (58.6)	0.3102
2–3	28	6.7 (4.7–9.0)		27	13 (48.1)	
Visceral involvement						
No	225	10.6 (8.9–11.6)	0.6604	212	121 (57.1)	0.7169
Yes	38	10.0 (7.1–13.9)		36	19 (52.8)	
Treatment line						
1st	59	11.5 (9.5–19.8)	0.0245	56	31 (55.4)	1.000
2nd	84	10.6 (8.3–13.6)		78	44 (56.4)	
3rd	52	9.9 (6.7–13.3)		48	28 (58.3)	
$\geq$ 4th	66	8.5 (6.5–11.1)		64	35 (54.7)	

CBR clinical benefit rate, CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, NE not evaluable, PFS progression-free survival, PR partial response, PgR progesterone receptor, SD stable disease